FDA Approves First Size-Adjustable Artificial Heart Valve for Pediatric Patients

The US Food and Drug Administration (FDA) has approved the Autus Size-Adjustable Valve, a medical device designed to expand post-surgery to accommodate a child’s growth. Developed by Edwards, this artificial pulmonary valve addresses a critical need for children with congenital heart defects, who previously required multiple surgeries to replace valves as they grew. According to the National Library of Medicine, approximately 400,000 children are born in the US annually with congenital heart disease, with 30 percent of cases involving valve abnormalities.

The Autus valve can be implanted in toddlers and preschool-aged children at an initial diameter of 13 millimeters. Utilizing a balloon catheter, surgeons can expand the device post-surgery to reach a maximum diameter of 22 millimeters, matching the size of adult valves. This capability significantly reduces the risks associated with repeated operations for conditions such as stenosis and atresia, which the Centers for Disease Control and Prevention notes affect roughly 4,200 infants in the United States every year.

Beyond its adjustability, the Autus valve is the first of its kind to utilize polymeric material for its flaps. Traditional implants typically rely on synthetic flaps derived from animal materials, which often harden and degrade more rapidly in pediatric patients. FDA follow-up data from the first year indicates that the Autus model demonstrates superior durability compared to existing alternatives. By keeping pace with the physical development of the patient, the device aims to improve long-term outcomes for children requiring pulmonary valve replacement.

What to watch: Clinical adoption rates and long-term durability data for the new polymeric material.

Editor's note: Accurate and well-structured report incorporating nearly all source facts and figures.